Boehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, as price competition began to affect its biggest selling drug Spiriva. The German pharma's ...
As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO. Formerly the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results